1. Home
  2. Publications

Publications

Cost-effectiveness of community-based household tuberculosis contact management for children in Cameroon and Uganda: a modelling analysis of a cluster-randomised trial.

Abstract

BACKGROUND: WHO recommends household contact management (HCM) including contact screening and tuberculosis-preventive treatment (TPT) for eligible children.

Nyashadzaishe Mafirakureva Boris K Tchounga Sushant Mukherjee Boris Tchakounte Youngui Bob Ssekyanzi Leonie Simo et al.
Lancet Glob Health; doi: https://doi.org/10.1016/S2214-109X(23)00451-5. Epub 2023 10 30
Tuberculosis Cameroon Uganda

Acceptability of decentralizing childhood tuberculosis diagnosis in low-income countries with high tuberculosis incidence: Experiences and perceptions from health care workers in Sub-Saharan Africa and South-East Asia.

Abstract

Decentralizing childhood tuberculosis services, including diagnosis, is now recommended by the WHO and could contribute to increasing tuberculosis detection in high burden countries.

Joshi B De Lima YV Massom DM Kaing S Banga MF Kamara ET Sesay S Borand L Taguebue JV Moh R Khosa C Breton G Mwanga-Amumpaire J Bonnet M Wobudeya E Marcy O Orne-Gliemann J
PLOS global public health 2023 ; 3(10); . doi: 10.1371/journal.pgph.0001525. Epub 2023 10 11

Abacavir drug exposures in African children under 14 kg using paediatric solid fixed dose combinations according to World Health Organization weight bands.

Abstract

BACKGROUND: The pharmacokinetics of abacavir (ABC) in African children living with HIV (CLHIV) weighing

Chupradit S Wamalwa DC Maleche-Obimbo E Kekitiinwa AR Mwanga-Amumpaire J Bukusi EA Nyandiko WM Mbuthia JK Swanson A Cressey TR Punyawudho B Musiime V
Journal of the Pediatric Infectious Diseases Society 2023 Oct 05; . doi: 10.1093/jpids/piad082. Epub 2023 10 05
Abacavir African children Dose optimization NONMEM Population pharmacokinetics

Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon

Abstract

BACKGROUND: Although the first year of the COVID-19 pandemic in Africa did not produce the expected catastrophe, the true impact of COVID-19 in the Cameroonian population was unclear.

J. Eyong K.N. Fai B. Nikolay E. Gignoux R. Nsaibirni D. Buri et al.
Scientific African 22 (2023) e01925; doi.org/10.1016/j.sciaf.2023.e01925
Mortality Seroprevalence SARS-CoV-2 Cameroon

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.

Abstract

BACKGROUND: Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB).

Sauer SM Mitnick CD Khan U Hewison C Bastard M Holtzman D Law S Khan M Padayachee S Ahmed S Isani AK Krisnanda A Vilbrun SC Bektasov S Kumsa A Docteur W Tintaya K McNicol M Atshemyan H Voynilo T Thwe TT Seung K Rich M Huerga H Khan P Franke M
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Sep 29; . doi: 10.1093/cid/ciad589. Epub 2023 09 29
MDR-TB competing events inverse-probability weighting missing follow-up post-treatment recurrence

Time to treatment initiation and HIV viral suppression in people diagnosed with HIV-1 during COVID-19 pandemic in ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).

Abstract

OBJECTIVES: The Covid-19 pandemic's impact on initiation and effectiveness of antiretroviral therapy (ART) in people diagnosed with HIV remains unclear.

Ben Farhat J Hessamfar M Farbos S Desclaux A Dumondin G Ferrand H Greib C Castan B Rispal P Duffau P Leleux O Perrier A Wittkop L Bonnet F Barger D
Journal of acquired immune deficiency syndromes (1999) 2023 Sep 28; . doi: 10.1097/QAI.0000000000003310. Epub 2023 09 28

Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

Abstract

High-Dose Rifampicin Regimen for Pulmonary TuberculosisThis randomized, controlled trial tested the efficacy and safety of high-dose rifampicin (1200 or 1800 mg/d) as part of the treatment regimen for pulmonary tuberculosis.

Jindani A Atwine D Grint D Bah B Adams J Ticona ER Shrestha B Agizew T Hamid S Jamil B Byamukama A Kananura K Mugisha Taremwa I Bonnet M Camara LM Bah-Sow OY Bah KS Bah NM Sow M Ticona Huaroto CE Mugruza Pineda R Tandukar B Raya BB Shrestha N Mathoma A Mathebula-Modongo UP Basotli J Irfan M Begum D Muzammil A Ahmed I Hasan R Burgos MV Sultan F Hassan M Masood I Robb C Decker J Grubnic S Butcher PD Witney A Dhillon J Munshi T Fielding K Harrison TS
NEJM evidence 2023 Sep ; 2(9); . doi: 10.1056/EVIDoa2300054. Epub 2023 08 22

Physiotherapy and associated factors affecting mouth opening changes in noma patients during initial hospitalization at an MSF-supported hospital in Northwest Nigeria-A retrospective cohort study.

Abstract

Noma is a rapidly progressing infection of the oral cavity, which can cause the disintegration of the cheek, nose and eye, in under a week.

Oluwalomola OV Briskin E Olaleye M Samuel J Oluyide B Sherlock M Adetunji AS Amirtharajah M
PLOS global public health 2023 ; 3(9); . doi: 10.1371/journal.pgph.0001995. Epub 2023 09 01

Evidence of HIV incidence reduction in young women, but not in adolescent girls, in KwaZulu-Natal, South Africa.

Abstract

OBJECTIVES: We estimated changes in the HIV incidence from 2013-2018 in Eshowe/Mbongolwane, KwaZulu-Natal, South Africa where Médecins Sans Frontières is engaged in providing HIV testing and care since 2011.

Mhlanga L Welte A Grebe E Ohler L Van Cutsem G Huerga H Conan N
IJID regions 2023 Sep ; 8; . doi: 10.1016/j.ijregi.2023.07.004. Epub 2023 07 13
ART Cross-sectional surveys HIV Incidence Prevalence Recency tests